AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Klotho Neurosciences to Host Inaugural Conference on Klotho-Based Therapies & Diagnostics
ByAinvest
Tuesday, Sep 9, 2025 12:44 am ET1min read
Klotho Neurosciences, a biotech company developing therapies for neurodegenerative diseases based on Klotho, announced that CEO Dr. Joseph Sinkule will attend the inaugural Klotho Conference & Scientific Seminar. The event, featuring research on Klotho-based therapies and diagnostics for ALS, Alzheimer's, and longevity, will take place at the UC-Irvine Beal Applied Innovation Center from September 15-16, 2025. Dr. Sinkule will be available to meet with investors and potential partners. Interested parties can contact [email protected].
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, has announced that CEO and Chairman Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event, the first of its kind, will be held at the UC-Irvine Beal Applied Innovation Center in Irvine, California, from September 15-16, 2025 [1].The conference will feature presentations by the company's key scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch. Their research will focus on Klotho gene therapy for treating ALS, Alzheimer's disease, and longevity. Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact [email protected] for more information [2].
Klotho Neurosciences is dedicated to developing innovative, disease-modifying cell and gene therapies using a protein derived from the "anti-aging" human Klotho gene (s-KL). The company's portfolio includes proprietary cell and gene therapy programs and genomics-based diagnostic assays, aimed at transforming the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease [1].
The company's forward-looking statements, which include descriptions of future commercial operations, are subject to risks and uncertainties. These include the company's ability to implement its business plans, identify and realize additional opportunities, and meet or exceed its financial projections, as well as changes in the regulatory or competitive environment [1].
References:
[1] https://www.prnewswire.com/news-releases/klotho-neurosciences-ceo-to-attend-inaugural-conference--scientific-seminar-302548238.html
[2] https://www.stocktitan.net/news/KLTO/klotho-neurosciences-ceo-to-attend-inaugural-conference-scientific-4lbht6bpw3v1.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet